New diabetes drug HM15275 enters Mid-Stage trial
NCT ID NCT07527650
First seen Apr 21, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study tests a new medicine called HM15275 in 180 adults with type 2 diabetes. Participants must be on diet and exercise or a stable dose of metformin. The goal is to see if the drug safely lowers blood sugar levels over 36 weeks compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Translational Research Institute
Orlando, Florida, 32804, United States
Contact
-
Lucas Research, Inc.
Morehead City, North Carolina, 28557, United States
Conditions
Explore the condition pages connected to this study.